| PD-1/PD-L1抑制剂治疗晚期肝细胞癌的研究进展 |
| |
| 引用本文： | 刘红燕,杨平. PD-1/PD-L1抑制剂治疗晚期肝细胞癌的研究进展[J]. 中国新药与临床杂志, 2021, 0(2): 81-86 |
| |
| 作者姓名： | 刘红燕 杨平 |
| |
| 作者单位： | 安徽医科大学海军临床学院;中国人民解放军总医院第六医学中心肿瘤科 |
| |
| 摘 要： | 随着肿瘤免疫治疗的不断应用,免疫检查点抑制剂(ICI)治疗肿瘤的相关临床研究开展广泛.多项研究表明,以程序性死亡受体/配体1(PD-1/PD-L1)抑制剂为代表的ICI在肝细胞癌治疗中取得了较好的疗效并改善了患者生存期;除单药治疗外,PD-1/PD-L1抑制剂还能与化疗、靶向药物及其他ICI联合治疗.但免疫治疗相关不良...
|
| 关 键 词： | 癌 肝细胞 程序性死亡受体/配体抑制剂 临床研究 肿瘤免疫治疗 |
Research progress of PD-1/PD-L1 inhibitors in treating advanced hepatocellular carcinoma |
| |
| LIU Hong-yan,YANG Ping. Research progress of PD-1/PD-L1 inhibitors in treating advanced hepatocellular carcinoma[J]. Chinese Journal of New Drugs and Clinical Remedies, 2021, 0(2): 81-86 |
| |
| Authors: | LIU Hong-yan YANG Ping |
| |
| Affiliation: | (Affiliated Naval Clinical College of Anhui Medical University,Hefei ANHUI 230032,China;Department of Oncology,the Sixth Medical Center of PIA General Hospital,BEIJING 100048,China) |
| |
| Abstract: | With the continuous application of tumor immunotherapy, clinical studies on immune checkpoint inhibitors(ICI) in the treatment of tumor have been widely carried out. A number of studies have shown that ICI, represented by programmed death receptor/ligand 1(PD-1/PD-L1) inhibitors, has achieved good efficacy in the treatment of hepatocellular carcinoma and improved patient survival. In addition to single-drug therapy, it can also be combined with chemotherapy, targeted drugs and other ICI therapy. However, immunotherapy-related adverse events limited the clinical application of PD-1/PD-L1 inhibitors, and the biological markers need to be defined to evaluate the efficacy. |
| |
| Keywords: | carcinoma,hepatocytes programmed death receptor/ligand inhibitors clinical research tumor immunotherapy |
| 本文献已被 维普 等数据库收录！ |
|
